Barclays: Teva’s reshuffle hits morale, Levin remains popular

Barclays says that Jeremy Levin remained popular with Teva’s rank-and-file and this will be destabilizing to morale.

By YOSSI NISSAN/GLOBES
November 4, 2013 02:59
Teva CEO JEREMY LEVIN

Teva CEO JEREMY LEVIN 150. (photo credit: Reuters)

1


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS